Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc. operates as a global healthcare company focused on the development and production of stabilized hypochlorous acid (HOCl) products. Founded in 1999 in Petaluma, California, as Micromed Laboratories Inc., the company has undergone several transformations, changing its name to Oculus Innovative Sciences in 2001 and finally to Sonoma Pharmaceuticals in 2016. The company was founded by Hojabr Alimi and Linda Alimi in April 1999. A significant milestone was achieved in 2004 with the introduction of a stable, patented HOCl-based wound care formulation, known as 'Microcyn® Wound Care' in the US.

The core of Sonoma's product portfolio is its proprietary Microcyn® Technology, a highly stable formulation of HOCl that mimics the natural compound produced by the human immune system to combat pathogens. This technology serves as the foundation for a wide range of products across several markets, including dermatology, wound care, eye care, nasal care, oral care, podiatry, and animal health. The company's offerings, which are available both over-the-counter (OTC) and via prescription, address conditions such as minor irritations, cuts, burns, and more serious wounds like diabetic ulcers. Products include sprays, gels, and solutions marketed under various brand names like Lasercyn, Regenacyn, and Ocucyn.

Sonoma's business model is a hybrid, combining direct sales with a network of strategic partnerships, licensing agreements, and distributors that span across North America, Europe, Asia, and Latin America. Revenue is primarily generated through the sale of its products to healthcare providers, distributors, and consumers. The company has pursued a strategy of relaunching certain product lines, such as its prescription dermatology portfolio, through a direct sales model to enhance its market presence. For the fiscal year ending March 31, 2025, the company reported total revenues of $14.3 million. Sonoma Pharmaceuticals is a publicly-traded company, listed on the Nasdaq under the ticker symbol SNOA.

Keywords: hypochlorous acid, HOCl products, Microcyn Technology, wound care, dermatology solutions, pharmaceutical manufacturing, skincare products, animal healthcare, eye care solutions, oral care products, medical devices, topical treatments, antimicrobial solutions, FDA clearance, global distribution, pharmaceutical licensing, specialty pharmaceuticals, over-the-counter medicine, prescription dermatology, Nasdaq SNOA